Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Rock Creek Pharmaceuticals Inc is engaged in research, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders, utilizing its proprietary compounds. The company is focusing its drug development efforts on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its proprietary formulations of its lead compound anatabine citrate. Its objective is to develop, obtain approval for, and commercialize pharmaceutical products utilizing its anatabine-based and related compounds.
Sarasota, FL, 34243